{"id":913677,"date":"2025-11-25T09:42:03","date_gmt":"2025-11-25T14:42:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/"},"modified":"2025-11-25T09:42:03","modified_gmt":"2025-11-25T14:42:03","slug":"pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/","title":{"rendered":"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment<\/b><\/p>\n<p>LAS VEGAS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nPharmaCyte Biotech, Inc. (Nasdaq:PMCB) (\u201cPharmaCyte\u201d or the \u201cCompany\u201d), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company\u2019s strategic approach to capital deployment and strengthening its already solid financial position.\n<\/p>\n<p>\nFollowing the monetization of the stake, PharmaCyte\u2019s cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 2025. This transaction highlights the Company\u2019s ability to identify and execute on high-quality opportunities that deliver strong returns while maintaining a conservative risk profile.\n<\/p>\n<p>\n\u201cOur successful monetization of the Femasys position demonstrates the effectiveness of our strategic and disciplined capital allocation approach,\u201d said Josh Silverman, PharmaCyte Chief Executive Officer. \u201cWe are committed to deploying shareholder capital intelligently, balancing near-term returns with opportunities that can deliver sustained value creation.\u201d\n<\/p>\n<p>\nAs valued in the most recently filed 10Q, PharmaCyte Biotech has approximately $25 million in marketable securities, in addition to roughly $20 million in cash, inclusive of the proceeds from the Femasys monetization. Despite this strengthened financial position, PharmaCyte\u2019s stock currently trades at a recent price of $0.65 per share, with approximately 6.8 million shares outstanding.\n<\/p>\n<p>\nPharmaCyte plans to continue pursuing value-accretive investment opportunities and disciplined operational management to further enhance shareholder returns.\n<\/p>\n<p><b>About PharmaCyte Biotech, Inc.<\/b><\/p>\n<p>\nPharmaCyte Biotech, Inc. (NASDAQ: PMCB) is a biotechnology company focused on developing cellular therapies for cancer, diabetes, and other serious diseases. In parallel, the Company employs a disciplined investment strategy designed to strengthen its financial position and maximize shareholder value through strategic cash deployment.\n<\/p>\n<p><b>Safe Harbor<\/b><\/p>\n<p>\nThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of PharmaCyte\u2019s management and Board of Directors. Any statements contained in this press release which do not describe historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results, performance, and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, whether our exploration of additional opportunities to create new paths toward shareholder value is successful, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise. More information about PharmaCyte Biotech can be found at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpharmacyte.com&amp;esheet=54363508&amp;newsitemid=20251125795950&amp;lan=en-US&amp;anchor=https%3A%2F%2Fpharmacyte.com&amp;index=1&amp;md5=81ec46559e00163e1bc3f73a23784fb5\">https:\/\/pharmacyte.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251125795950\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251125795950\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Contact:<\/p>\n<p>CORE IR<\/p>\n<p><a rel=\"nofollow\" href=\"mailto:ir@pharmacyte.com\">ir@pharmacyte.com<br \/>\n<\/a><\/p>\n<p>Media Contact:<\/p>\n<p>CORE IR<\/p>\n<p>Email: <a rel=\"nofollow\" href=\"mailto:pr@coreir.com\">pr@coreir.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Nevada United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Diabetes Other Health General Health Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment LAS VEGAS&#8211;(BUSINESS WIRE)&#8211; PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (\u201cPharmaCyte\u201d or the \u201cCompany\u201d), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company\u2019s strategic approach to capital deployment and strengthening its already solid financial position. Following the monetization of the stake, PharmaCyte\u2019s cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 2025. This transaction highlights the Company\u2019s ability to identify and execute on high-quality opportunities that deliver strong returns while maintaining a conservative risk profile. \u201cOur successful monetization of the Femasys position demonstrates the effectiveness of our strategic and disciplined &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-913677","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment LAS VEGAS&#8211;(BUSINESS WIRE)&#8211; PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (\u201cPharmaCyte\u201d or the \u201cCompany\u201d), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company\u2019s strategic approach to capital deployment and strengthening its already solid financial position. Following the monetization of the stake, PharmaCyte\u2019s cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 2025. This transaction highlights the Company\u2019s ability to identify and execute on high-quality opportunities that deliver strong returns while maintaining a conservative risk profile. \u201cOur successful monetization of the Femasys position demonstrates the effectiveness of our strategic and disciplined &hellip; Continue reading &quot;PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T14:42:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment\",\"datePublished\":\"2025-11-25T14:42:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/\"},\"wordCount\":530,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/\",\"name\":\"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-11-25T14:42:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/","og_locale":"en_US","og_type":"article","og_title":"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Market Newsdesk","og_description":"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment LAS VEGAS&#8211;(BUSINESS WIRE)&#8211; PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (\u201cPharmaCyte\u201d or the \u201cCompany\u201d), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company\u2019s strategic approach to capital deployment and strengthening its already solid financial position. Following the monetization of the stake, PharmaCyte\u2019s cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 2025. This transaction highlights the Company\u2019s ability to identify and execute on high-quality opportunities that deliver strong returns while maintaining a conservative risk profile. \u201cOur successful monetization of the Femasys position demonstrates the effectiveness of our strategic and disciplined &hellip; Continue reading \"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-25T14:42:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment","datePublished":"2025-11-25T14:42:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/"},"wordCount":530,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/","name":"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-11-25T14:42:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-underscoring-strategic-capital-deployment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=913677"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913677\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=913677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=913677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=913677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}